GlassScriptPhysician profile
Emily Hightower
NPI 1336870781
$6,881.72
in general payments reported to CMS, 2019-2025
54 companies · $2,102 in 2025
The $2,102 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $629 · 2023: $2,166 · 2024: $1,984 · 2025: $2,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,152 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,152.42 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $776.13 | 2022-2025 | Imfinzi, Tagrisso, Calquence |
| Regeneron Healthcare Solutions, INC. | $632.35 | 2022-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $615.26 | 2022-2025 | Erleada, Akeega, Balversa |
| Eisai INC. | $513.59 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $366.59 | 2023-2025 | |
| Pfizer INC. | $299.99 | 2022-2025 | |
| Daiichi Sankyo INC. | $280.30 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $257.59 | 2022-2025 | Monjuvi, Pemazyre, Zynyz |
| Merck Sharp & Dohme LLC | $257.47 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Genzyme Corporation | $256.08 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.26 | 2022-2025 | Iclusig, Alunbrig, Ninlaro |
| Tersera Therapeutics LLC | $197.01 | 2023-2025 | Xermelo, Zoladex, Quzyttir |
| Array Biopharma INC | $154.61 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Caris Mpi, INC. | $135.79 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $127.92 | 2023 | Orserdu |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $124.52 | 2022-2025 | |
| Abbvie INC. | $119.12 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $104.85 | 2023 | Myrisk |
| Genentech USA, INC. | $103.68 | 2023-2025 | Polivy, Lunsumio, Tecentriq |
| Blueprint Medicines Corporation | $98.70 | 2023-2024 | Ayvakit |
| Adc Therapeutics America, INC. | $89.06 | 2022-2025 | |
| Emd Serono, INC. | $88.32 | 2022-2025 | |
| Taiho Oncology, INC. | $86.75 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $72.45 | 2023-2025 | Monoferric, Cosela |
| Genmab U.S., INC. | $65.50 | 2024-2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $61.58 | 2022-2025 | Qinlock, Romvimza |
| Sumitomo Pharma America, INC. | $61.18 | 2024 | Orgovyx |
| Exelixis INC. | $60.04 | 2023-2024 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.67 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $55.26 | 2022-2023 | Xpovio |
| Celgene Corporation | $51.24 | 2025 | Reblozyl |
| Servier Pharmaceuticals LLC | $48.18 | 2024-2025 | |
| Puma Biotechnology, INC. | $44.89 | 2023-2024 | |
| Beigene USA, INC. | $37.13 | 2024 | Tevimbra, Brukinsa |
| Lilly USA, LLC | $36.48 | 2023 | Verzenio, Retevmo, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $35.03 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $32.31 | 2023-2024 | Soliris, Ultomiris |
| Mirati Therapeutics, INC. | $31.46 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $19.44 | 2025 | Onivyde |
| Pharmaessentia USA Corporation | $18.61 | 2023 | Besremi |
| Kite Pharma, INC. | $17.07 | 2025 | Yescarta |
| Corcept Therapeutics | $16.70 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $16.38 | 2024 | Ojjaara |
| Syndax Pharmaceuticals, INC. | $16.11 | 2025 | |
| Immunogen, INC. | $16.10 | 2023 | Elahere |
| Aveo Pharmaceuticals, INC. | $15.82 | 2023 | Fotivda |
| Beone Medicines USA, INC. | $14.52 | 2025 | Tevimbra |
| Cumberland Pharmaceuticals, INC. | $14.45 | 2025 | Sancuso |
| Agios Pharmaceuticals, INC. | $14.30 | 2025 | Pyrukynd |
| Apellis Pharmaceuticals, INC. | $14.02 | 2023 | Empaveli |
| Springworks Therapeutics, INC. | $13.67 | 2024 | Ogsiveo |
| Spectrum Pharmaceuticals INC. | $13.20 | 2024 | Rolvedon |
| Myovant Sciences INC. | $12.75 | 2022 | |
| Veracyte, INC. | $12.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hightower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.